BA
PGNX

Boston Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Boston Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-23,000
Closed -$142K – 648
2019
Q2 		$142K Hold
23,000
– – 0.01% 627
2019
Q1 		$107K Buy
23,000
+10,000
+77% +$45.2K 0.01% 625
2018
Q4 		$55K Buy
+13,000
New +$66.2K ﹤0.01% 622

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Boston Advisors's PGNX Position: Q3 2019 in Review

Boston Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2019, closing a stake of 23,000 shares — an estimated $142K sold.

Boston Advisors first reported a position in PGNX in Q4 2018 and held it in 3 quarters. The position peaked at $142K in Q2 2019. 135 funds tracked by Wall St. Rank hold PGNX as of Q3 2019.

  • Boston Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2019 after selling out during the quarter.
  • Boston Advisors sold 23,000 Progenics Pharmaceuticals Inc shares in Q3 2019, an estimated $142K.
  • Boston Advisors first reported a position in Progenics Pharmaceuticals Inc in Q4 2018 and held it in 3 quarters.
  • Boston Advisors's Progenics Pharmaceuticals Inc position peaked at $142K in Q2 2019.
  • 135 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.